<DOC>
	<DOC>NCT01058759</DOC>
	<brief_summary>Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.</brief_summary>
	<brief_title>Taxotere-Enoxaparin-(ENOXA)-Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent Men and women aged 18 and older Locally Advanced or Metastatic Nonsmall Cell Lung Cancer stage IIIB/IV without any previous therapy Life expectancy at least 12 weeks EOCG performance &lt; 1 Appropriate renal and hepatic function Appropriate Hematology No bleeding events within 4 weeks prior to randomization No indication for prophylactic or therapeutic anticoagulation therapy Appropriate methods of contraception (both: men and women) for women of childbearing potential negative urine pregnancy test within 7 day prior to randomization Capability for s.c. injection of Enoxaparin every 24 hrs History of cancer other than NSCLC Known contraindication for Enoxaparin e.g. HIT, Known contraindication for Docetaxel, Cisplatin, Carboplatin or comedication Participation in any other clinical trials within 30 days prior to randomization Any known medical condition that does not allow therapy according to study protocol Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>Locally Advanced or Metastatic Non-small Cell Lung Cancer stadium IIIb/IV</keyword>
</DOC>